Literature DB >> 10583605

Immunomodulatory effect of a plasmid expressing CD40 ligand on DNA vaccination against human immunodeficiency virus type-1.

A Ihata1, S Watabe, S Sasaki, A Shirai, J Fukushima, K Hamajima, J Inoue, K Okuda.   

Abstract

CD40 ligand is a costimulatory molecule which acts a potent immunomodulator. We found the mice inoculated with human CD40 ligand expression plasmid (pMEhCD40L) combined with human immunodeficiency virus type-1 (HIV-1) DNA vaccine exhibited both humoral and cellular antigen-specific immunological enhancement. The expression of hCD40L induced predominantly antigen-specific immunoglobulin G (IgG) antibody response while it failed to induce mucosal IgA response. Delayed-type hypersensitivity (DTH) and cytotoxic T lymphocyte (CTL) activity were induced in a dose-dependent manner. Examination of the relative levels of the two IgG subclasses showed that co-injection of pMEhCD40L enhanced IgG2a response without suppressing IgG1 response. Similarly, the expression of pMEhCD40L enhanced not only T helper 1 (Th1)- but also Th2-type cytokine production. In conclusion, co-inoculation of pMEhCD40L with DNA vaccine was shown to be a useful way to enhance CTL responses without suppressing the humoral immune response in acquired immune deficiency syndrome (AIDS) patients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10583605      PMCID: PMC2326951          DOI: 10.1046/j.1365-2567.1999.00879.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  33 in total

Review 1.  The expansive role of CD40 and its ligand, gp39, in immunity.

Authors:  T M Foy; F H Durie; R J Noelle
Journal:  Semin Immunol       Date:  1994-10       Impact factor: 11.130

Review 2.  The role of CD40 and its ligand (gp39) in peripheral and central tolerance and its contribution to autoimmune disease.

Authors:  F H Durie; T M Foy; R J Noelle
Journal:  Res Immunol       Date:  1994 Mar-Apr

3.  T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions.

Authors:  S P Schoenberger; R E Toes; E I van der Voort; R Offringa; C J Melief
Journal:  Nature       Date:  1998-06-04       Impact factor: 49.962

4.  Protective immunity by intramuscular injection of low doses of influenza virus DNA vaccines.

Authors:  J B Ulmer; R R Deck; C M DeWitt; A Friedman; J J Donnelly; M A Liu
Journal:  Vaccine       Date:  1994-12       Impact factor: 3.641

5.  Human immunodeficiency virus (HIV) nef-specific cytotoxic T lymphocytes in noninfected heterosexual contact of HIV-infected patients.

Authors:  P Langlade-Demoyen; N Ngo-Giang-Huong; F Ferchal; E Oksenhendler
Journal:  J Clin Invest       Date:  1994-03       Impact factor: 14.808

6.  Strong immunogenicity of a multicomponent peptide vaccine developed with the branched lysine oligopeptide method for human immunodeficiency virus infection.

Authors:  K Okuda; T Kaneko; T Yamakawa; S Tanaka; T Shigematsu; A Yamamoto; K Hamajima; K Nakajima; S Kawamoto; P Phanuphak
Journal:  J Mol Recognit       Date:  1993-09       Impact factor: 2.137

7.  Recombinant CD40 ligand exerts potent biologic effects on T cells.

Authors:  W C Fanslow; K N Clifford; M Seaman; M R Alderson; M K Spriggs; R J Armitage; F Ramsdell
Journal:  J Immunol       Date:  1994-05-01       Impact factor: 5.422

Review 8.  The role of CD40 in the regulation of humoral and cell-mediated immunity.

Authors:  F H Durie; T M Foy; S R Masters; J D Laman; R J Noelle
Journal:  Immunol Today       Date:  1994-09

9.  Quantitative analysis of the human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 infection: differential CTL responses to HIV-1 and Epstein-Barr virus in late disease.

Authors:  A Carmichael; X Jin; P Sissons; L Borysiewicz
Journal:  J Exp Med       Date:  1993-02-01       Impact factor: 14.307

10.  Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha.

Authors:  F Sallusto; A Lanzavecchia
Journal:  J Exp Med       Date:  1994-04-01       Impact factor: 14.307

View more
  7 in total

1.  Multimeric soluble CD40 ligand and GITR ligand as adjuvants for human immunodeficiency virus DNA vaccines.

Authors:  Geoffrey W Stone; Suzanne Barzee; Victoria Snarsky; Kristin Kee; Celsa A Spina; Xiao-Fang Yu; Richard S Kornbluth
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

2.  CD40L-adjuvanted DNA/modified vaccinia virus Ankara simian immunodeficiency virus SIV239 vaccine enhances SIV-specific humoral and cellular immunity and improves protection against a heterologous SIVE660 mucosal challenge.

Authors:  Suefen Kwa; Lilin Lai; Sailaja Gangadhara; Mariam Siddiqui; Vinod B Pillai; Celia Labranche; Tianwei Yu; Bernard Moss; David C Montefiori; Harriet L Robinson; Pamela A Kozlowski; Rama Rao Amara
Journal:  J Virol       Date:  2014-06-11       Impact factor: 5.103

Review 3.  Vaccine development against HIV-1: current perspectives and future directions.

Authors:  Rebecca L Edgeworth; Juan Homero San; Jason A Rosenzweig; Nang L Nguyen; Jean D Boyer; Kenneth E Ugen
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

4.  Human immunodeficiency virus and leishmaniasis.

Authors:  Navid Ezra; Maria Teresa Ochoa; Noah Craft
Journal:  J Glob Infect Dis       Date:  2010-09

5.  Incorporation of CD40 ligand into the envelope of pseudotyped single-cycle Simian immunodeficiency viruses enhances immunogenicity.

Authors:  Fan-ching Lin; Yue Peng; Leslie A Jones; Paulo H Verardi; Tilahun D Yilma
Journal:  J Virol       Date:  2008-11-26       Impact factor: 5.103

6.  Codon optimization of the tat antigen of human immunodeficiency virus type 1 generates strong immune responses in mice following genetic immunization.

Authors:  Lakshmi Ramakrishna; Krishnamurthy Kumar Anand; Kumarasamypet M Mohankumar; Udaykumar Ranga
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

Review 7.  HIV DNA Vaccine: Stepwise Improvements Make a Difference.

Authors:  Barbara K Felber; Antonio Valentin; Margherita Rosati; Cristina Bergamaschi; George N Pavlakis
Journal:  Vaccines (Basel)       Date:  2014-05-14
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.